The Microbiome as a Therapeutic Target for Metabolic Diseases

Large-scale alterations of the gut micro biota and its Microbiome (gene content) are associated with Metabolic diseases, especially type 2 diabetes and obesity and are responsive to weight loss, are growing global health‐care concerns. Gut microbes can impact host metabolism via signaling pathways in the gut, with effects on inflammation, insulin resistance, and deposition of energy in fat stores. New therapeutic approaches are urgently needed to address the emerging epidemic of obesity and diabetes. Restoration of the gut micro biota to a healthy state may ameliorate the conditions associated with obesity and help maintain a healthy weight. The Microbiome, the collective genomic and metabolic potential of the gut micro biota, may have a key role in many chronic diseases through its mitigation of immune‐inflammatory responses. 

    Related Conference of The Microbiome as a Therapeutic Target for Metabolic Diseases

    March 18-19, 2024

    53rd World Congress on Microbiology

    Zurich, Switzerland
    May 09-10, 2024

    16th International Virology Summit

    Barcelona, Spain

    The Microbiome as a Therapeutic Target for Metabolic Diseases Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in